CHPA Dietary Supplements Committee members fully support the proposed changes to the labeling requirements for health claims regarding calcium and osteoporosis. These proposed changes amend the regulation authorizing health claims on the relationship between calcium and a reduced risk of osteoporosis.
The PCPC and CHPA are pleased to provide these comments in response to FDA's proposed amendment to the final monograph for OTC sunscreen drug products for human use.
Request for extension of comment period regarding Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs that are Regulated Under a Biologics License Application, and Animal Drugs.
The Consumer Healthcare Products Association welcomes the opportunity to present its recommendations for CFSAN’s top priorities for the upcoming fiscal year and congratulates FDA on its achievements of the previous year.
While DXM is used safely by millions of Americans, some teenagers and young adults are intentionally abusing large quantities of medicines containing DXM in an effort to get high.
CHPA appreciates the opportunity to provide comments to the Food and Drug Administration on the proposed experimental study of qualified health claims about omega-3 fatty acids.
CHPA appreciates the comments of FDA in the February 2006, feedback letter and understands that these comments are FDA’s best advice on designing a protocol to address the safety and efficacy of benzocaine. We have included a revised final protocol for your final review.
